249 related articles for article (PubMed ID: 33563899)
1. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
Garcia-Gutiérrez V; Luna A; Alonso-Dominguez JM; Estrada N; Boque C; Xicoy B; Giraldo P; Angona A; Alvarez-Larrán A; Sanchez-Guijo F; Ramírez MJ; Mora E; Vélez P; Rosell A; Colorado Araujo M; Cuevas B; Sagüés M; Cortes M; Encinas MP; Casado Montero LF; Moreno Vega M; Serrano L; Gomez V; Garcia-Hernandez C; Lakhwani S; Paz Coll A; de Paz R; Suarez-Varela S; Fernandez-Ruiz A; Perez Lopez R; Ortiz-Fernández A; Jiménez-Velasco A; Steegmann-Olmedillas JL; Hernández-Boluda JC
Blood Cancer J; 2021 Feb; 11(2):16. PubMed ID: 33563899
[No Abstract] [Full Text] [Related]
2. Asciminib as a new option in the treatment of chronic myeloid leukemia.
İbiş B; Tiribelli M; Eşkazan AE
Future Oncol; 2021 Dec; 17(36):5003-5005. PubMed ID: 34791894
[No Abstract] [Full Text] [Related]
3. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
Hughes TP; Mauro MJ; Cortes JE; Minami H; Rea D; DeAngelo DJ; Breccia M; Goh YT; Talpaz M; Hochhaus A; le Coutre P; Ottmann O; Heinrich MC; Steegmann JL; Deininger MWN; Janssen JJWM; Mahon FX; Minami Y; Yeung D; Ross DM; Tallman MS; Park JH; Druker BJ; Hynds D; Duan Y; Meille C; Hourcade-Potelleret F; Vanasse KG; Lang F; Kim DW
N Engl J Med; 2019 Dec; 381(24):2315-2326. PubMed ID: 31826340
[TBL] [Abstract][Full Text] [Related]
4. Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
Hall KH; Brooks A; Waller EK
Am J Hematol; 2021 Aug; 96(8):E293-E295. PubMed ID: 33971041
[No Abstract] [Full Text] [Related]
5. Asciminib in chronic myeloid leukemia: many questions still remain to be answered.
Eşkazan AE
Blood Cancer J; 2021 Apr; 11(4):81. PubMed ID: 33927187
[No Abstract] [Full Text] [Related]
6. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
Manley PW; Barys L; Cowan-Jacob SW
Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
[TBL] [Abstract][Full Text] [Related]
7. Breaking the mold: asciminib as a standard-of-care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting.
Yılmaz R; Eşkazan AE
Future Oncol; 2023 Mar; 19(8):545-547. PubMed ID: 37039036
[No Abstract] [Full Text] [Related]
8. High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation.
Uchida Y; Koyama D; Manabe K; Suzuki K; Asano N; Endo M; Fukatsu M; Sano T; Hayashi K; Takano M; Takahashi H; Kimura S; Ikezoe T
Intern Med; 2024 Mar; 63(5):717-720. PubMed ID: 37407456
[TBL] [Abstract][Full Text] [Related]
9. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
[TBL] [Abstract][Full Text] [Related]
10. Asciminib for the treatment of patients with chronic myeloid leukemia.
Cortes J
Clin Adv Hematol Oncol; 2021 Apr; 19(4):207-208. PubMed ID: 33989269
[No Abstract] [Full Text] [Related]
11. Asciminib: First Approval.
Deeks ED
Drugs; 2022 Feb; 82(2):219-226. PubMed ID: 35041175
[TBL] [Abstract][Full Text] [Related]
12. Asciminib (Scemblix) for chronic myeloid leukemia.
Med Lett Drugs Ther; 2023 Jun; 65(1678):e107-e108. PubMed ID: 37339100
[No Abstract] [Full Text] [Related]
13. Novel therapeutic approaches in chronic myeloid leukemia.
Özgür Yurttaş N; Eşkazan AE
Leuk Res; 2020 Apr; 91():106337. PubMed ID: 32200189
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population.
Kockerols CCB; Janssen JJWM; Blijlevens NMA; Klein SK; Van Hussen-Daenen LGM; Van Gorkom GGY; Smit WM; Van Balen P; Biemond BJ; Cruijsen MJ; Corsten MF; Te Boekhorst PAW; Koene HR; Van Sluis GL; Cornelissen JJ; Westerweel PE
Haematologica; 2023 Jan; 108(1):240-244. PubMed ID: 36073515
[No Abstract] [Full Text] [Related]
15. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.
Qiang W; Antelope O; Zabriskie MS; Pomicter AD; Vellore NA; Szankasi P; Rea D; Cayuela JM; Kelley TW; Deininger MW; O'Hare T
Leukemia; 2017 Dec; 31(12):2844-2847. PubMed ID: 28819281
[No Abstract] [Full Text] [Related]
16. Asciminib: an investigational agent for the treatment of chronic myeloid leukemia.
Breccia M; Colafigli G; Scalzulli E; Martelli M
Expert Opin Investig Drugs; 2021 Aug; 30(8):803-811. PubMed ID: 34130563
[No Abstract] [Full Text] [Related]
17. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P
J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981
[TBL] [Abstract][Full Text] [Related]
18. A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood-brain barrier.
Manley PW; Huth F; Moussaoui S; Schoepfer J
Bioorg Med Chem Lett; 2022 Mar; 59():128577. PubMed ID: 35065232
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors.
García-Gutiérrez V; Hernandez-Boluda JC
Expert Rev Hematol; 2022 Jun; 15(6):477-484. PubMed ID: 35583386
[TBL] [Abstract][Full Text] [Related]
20. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
Luna A; Pérez-Lamas L; Boque C; Giraldo P; Xicoy B; Ruiz Nuño C; Vega MM; Alvarez-Larrán A; Salamanca A; García-Noblejas A; Vall-Llovera F; Villalon L; De Las Heras N; Ramila E; Pérez-Encinas M; Cuevas B; Perez-Lopez R; Sanchez-Guijo F; Jiménez-Velasco A; Lakhwani S; Casado LF; Rosell A; Escola A; Fernández MJ; Garcia-Hernandez C; Cervero C; Mora E; Sagüés M; Suarez-Varela S; Vélez P; Carrascosa Mastell P; Bitaube RF; Serrano L; Cortes M; Vera Goñi JA; Steegmann JL; de Soria VGG; Alonso-Dominguez JM; Araujo MC; Coll AP; Hernandez-Boluda JC; García-Gutiérrez V
Ann Hematol; 2022 Oct; 101(10):2263-2270. PubMed ID: 35997804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
